Skip to main content
Clinical Trials/EUCTR2015-003947-21-PL
EUCTR2015-003947-21-PL
Active, not recruiting
Phase 1

’Dose dependent pain relieving efficacy and local tolerability of diclofenac oromucosal spray in the treatment of sore throat: A multicenter, parallel-group, double-blind, placebo controlled and randomized clinical study’’

FARMAKA Srl0 sites180 target enrollmentNovember 17, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
moderate or severe sore throat
Sponsor
FARMAKA Srl
Enrollment
180
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 17, 2015
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
FARMAKA Srl

Eligibility Criteria

Inclusion Criteria

  • ?Male or female outpatients
  • ?Aged 18 – 75 years
  • ?Evidence of acute viral tonsillopharyngitis not requiring antibiotic treatment as diagnosed by physician
  • ?Pain at swallowing (odynophagia) not less than 50 mm on a 100 mm VAS scale
  • ?Tonsillo\-Pharyngitis Score (TPS) \>6 points at baseline.
  • ?Disease onset within 48 hours prior to study inclusion, medically untreated.
  • ?If female of childbearing potential:
  • ?Have maintained reliable birth control (oral contraceptive, IUDs ) for at least one month before the enrollment and agree to maintain it throughout the study and
  • ?with negative pregnancy test (urine)
  • ?Subject who, in the opinion of the investigator, would understand the meaning of the information sheet, would be co\-operative and sufficiently reliable to use the medication as instructed, complete the diary and return for scheduled visits including assurance of availability for follow¬\-up call.

Exclusion Criteria

  • ?Known hypersensitivity to any component of the study medication and / or paracetamol
  • ?Hypersensivity to acetylsalicylic acid and any NSAIDs
  • ?Recognized alteration in hepatic or renal function or positive history of gastrointestinal disorders
  • ?Recognized glucose 6 dehydrogenase deficit
  • ?Streptococcal throat infection \- positive finding on Strep Test in commercial presentation available on the Polish market
  • ?Subject undergone to any oromucosal surgery 30 days before the enrollment date
  • ?Subject mentally not capable of adhering to the protocol
  • ?Subjects suffering from depression, epilepsy or other psychological disorders
  • ?Known impaired kidney, liver or lung function
  • ?Bronchopneumonia

Outcomes

Primary Outcomes

Not specified

Similar Trials